Current HIV/AIDS Reports

, 4:158 | Cite as

The role of safer injection facilities in the response to HIV/AIDS among injection drug users

  • Thomas Kerr
  • Jo Kimber
  • Kora DeBeck
  • Evan Wood


Many cities throughout the globe are experiencing ongoing infectious disease and overdose epidemics among injection drug users (IDUs). In particular, HIV has become endemic among IDUs in many settings. In an effort to reduce this and related public health concerns, medically supervised safer injecting facilities (SIFs), where IDUs can inject pre-obtained illicit drugs under the supervision of medical staff, have been established in several countries. The following review assesses the role that SIFs can play in reducing the harms associated with HIV infection among IDUs and points to ways in which SIFs can be further developed to better respond to the challenges associated with HIV/AIDS among this population.


Injection Drug User Addiction Treatment Needle Exchange Safe Injection Facility Access Addiction Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Joint United Nations Programme on HIV/AIDS: Report on the Global AIDS Epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2006.Google Scholar
  2. 2.
    Stein MD: Medical complications of intravenous drug use. J Gen Intern Med 1990, 5:249–257.PubMedCrossRefGoogle Scholar
  3. 3.
    Kerr T, Wood E, Grafstein E, et al.: High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health (Oxf) 2005, 27:62–66.CrossRefGoogle Scholar
  4. 4.
    Wood E, Kerr T, Montaner JS, et al.: Rationale for evaluating North America’s first medically supervised safer-injecting facility. Lancet Infect Dis 2004, 4:301–306.PubMedCrossRefGoogle Scholar
  5. 5.
    Drucker E: Drug prohibition and public health: 25 years of evidence. Public Health Rep 1999, 114:14–29.PubMedCrossRefGoogle Scholar
  6. 6.
    Garfield J, Drucker E: Fatal overdose trends in major US cities: 1990–1997. Addict Res Theory 2001, 9:425–436.Google Scholar
  7. 7.
    US Office of National Drug Control Policy: Estimation of Heroin Availability 1995–1998. Accessed August 2, 2007.
  8. 8.
    Wood E, Tyndall MW, Spittal PM, et al.: Supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ 2003, 168:165–169.PubMedGoogle Scholar
  9. 9.
    Schiraldi V, Holman B, Beatty P: Poor prescription: the costs of imprisoning drug offenders in the United States. Accessed August 2, 2007.
  10. 10.
    Tyndall MW, Currie S, Spittal P, et al.: Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003, 17:887–893.PubMedCrossRefGoogle Scholar
  11. 11.
    Boys A, Farrell M, Bebbington P, et al.: Drug use and initiation in prison: results from a national prison survey in England and Wales. Addiction 2002, 97:1551–1560.PubMedCrossRefGoogle Scholar
  12. 12.
    Broadhead RS, Kerr TH, Grund JP, Altice FL: Safer injection facilities in North America: their place in public policy and health initiatives. J Drug Issues 2002, 32:329–355.Google Scholar
  13. 13.
    Hedrich D: European Report on Drug Consumption Rooms. Luxembourg: Office for Official Publications of the European Communities; 2004.Google Scholar
  14. 14.
    Wood E, Kerr T, Small W, et al.: Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ 2004, 171:731–734.PubMedGoogle Scholar
  15. 15.
    Wood E, Tyndall MW, Montaner JS, Kerr T: Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ 2006, 175:1399–1404.PubMedGoogle Scholar
  16. 16.
    Medically Supervised Injecting Centre Evaluation Committee: Final Report of the Sydney Medically Supervised Injecting Centre. Sydney: MSIC Evaluation Committee; 2003.Google Scholar
  17. 17.
    Wood E, Tyndall MW, Li K, et al.: Do supervised injecting facilities attract higher risk injection drug users? Am J Prev Med 2005, 2:126–130.CrossRefGoogle Scholar
  18. 18.
    Wood E, Tyndall MW, Qui Z, et al.: Service uptake and characteristics of injection drug users utilizing North America’s first medically supervised safer injecting facility. Am J Public Health 2006, 96:770–773.PubMedCrossRefGoogle Scholar
  19. 19.
    Benninghoff F, Dubois-Arber F: Résultats de l’étude de la clientèle du Cactus Biel/Bienne 2001. Lausanne: Institut universitaire de médecine sociale et préventive; 2002.Google Scholar
  20. 20.
    Happel V: Konsumräume—eine effektive Massnahme zur Schadensminimierung bei DrogengebraucherInnen und BürgerInnen. Akzeptanz-Zeitschrift für akzeptierende Drogenarbeit und humane Drogenpolitik; 2000:30–36.Google Scholar
  21. 21.
    Benninghoff F, Solai S, Huissoud T, Dubois-Arber F: Evaluation de Quai 9 “Espace d’accueil et d’injection” à Genève: période 12/2001–12/2000. Lausanne: Institut universitaire de médecine sociale et préventive; 2003.Google Scholar
  22. 22.
    Kimber J, MacDonald M, van Beek I, et al.: Sydney Medically Supervised Injecting Centre: client characteristics and predictors of frequent attendance in the first 12-months of operation. J Drug Issues 2003, 33:639–649.Google Scholar
  23. 23.
    Zurhold H, Kreuzfeld N, Degkwitz P, Verthein U: Drogenkonsumräume. Gesundheitsförderung und Minderung öffentlicher Belastungen in europäischen Grossstädten. Freiburg: Lambertus; 2001.Google Scholar
  24. 24.
    Kemmesies U: Final Report: The Open Drug Scene and the Safe Injection Room Offers in Frankfurt am Main. Münster: INDRO; 1999.Google Scholar
  25. 25.
    Gerlach R, Schneider W: Consumption and Injecting Room (CIR) at INDRO, Münster, Germany: Annual Report 2002 (English Version). Münster: INDRO; 2003.Google Scholar
  26. 26.
    O’Connell J, Kerr T, Li K, et al.: Requiring help injecting independently predicts incident HIV infection among injection drug users. J Acquir Immune Defic Syndr 2005, 40:83–88.PubMedCrossRefGoogle Scholar
  27. 27.
    Wood E, Tyndall M, Stoltz J, et al.: Safer injecting education for HIV prevention within a medically supervised safer injecting facility. Int J Drug Policy 2005, 29:126–130.Google Scholar
  28. 28.
    Des Jarlais DC: Structural interventions to reduce HIV transmission among injecting drug users. AIDS 2000, 14(Suppl 1):S41–S46.PubMedCrossRefGoogle Scholar
  29. 29.
    Dubois-Arber F, Jeannin A, Spencer B, et al.: Evaluation of the AIDS Prevention Strategy in Switzerland (6th synthesis report 1996–1998). Lausanne: Institut universitaire de médicine sociale et préventive; 1999.Google Scholar
  30. 30.
    Benninghoff F, Geense R, Dubois-Arber F: Résultats de l’étude ‘La cliententèle des structures à bas seuil d’accessibilité en Suisse’ 2000 Bienne. Lausanne: Institut universitaire de médicine sociale et préventive; 2001.Google Scholar
  31. 31.
    Ronco C, Spuhler G, Coda P, Schopfer R: Evaluation for alley-rooms I, II, and III in Basel. Soc Prev Med 1996, 41:S58–S68.CrossRefGoogle Scholar
  32. 32.
    Jacob J, Rottmann J, Stöver H: Entstehung und Praxis eines Gesundheitsraumangebotes für Drogenkonsumierende. Abschlußbericht der einjährigen Evaluation des ‘drop-in Fixpunkt’ in Hannover. Oldenburg: Bibliotheks-und Informationssystem der Universität Oldenburg, Schriftenreihe Sucht-und Drogenforschung; 1999.Google Scholar
  33. 33.
    Nejedly MM, Burki C: Monitoring HIV Risk Behaviors in a Street Agency with Injection Room in Switzerland. Bern: Medizinischen Fakultat, Universitat Bern; 1996.Google Scholar
  34. 34.
    van der Poel A, Barendregt C, van de Mheen D: Drug consumption rooms in Rotterdam: an explorative description. Eur Addict Res 2003, 9:94–100.PubMedCrossRefGoogle Scholar
  35. 35.
    Meijer G, de Jong A, Koeter M, et al.: Evaluatie gebruiksruimnte Binnenstad-Zuid Groningen. Amsterdam/Groningen: Amsterdam Institute for Addiction Research/Intraval; 2001.Google Scholar
  36. 36.
    Wood E, Tyndall M, Stoltz J, et al.: Factors associated with syringe sharing among users of a medically supervised safer injection facility. Am J Infect Dis 2005, 1:50–54.CrossRefGoogle Scholar
  37. 37.
    Kerr T, Tyndall M, Li K, et al.: Safer injection facility use and syringe sharing in injection drug users. Lancet 2005, 366:316–318.PubMedCrossRefGoogle Scholar
  38. 38.
    Celentano DD, Vlahov D, Cohn S, et al.: Risk factors for shooting gallery use and cessation among intravenous drug users. Am J Public Health 1991, 81:1291–1295.PubMedCrossRefGoogle Scholar
  39. 39.
    Kimber J, Dolan K: Shooting gallery operation in the context of establishing a medically supervised injecting center: Sydney, Australia. J Urban Health 2007, 84:255–266.PubMedCrossRefGoogle Scholar
  40. 40.
    Wood E, Tyndall MW, Lai C, et al.: Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy 2006, 1:13.PubMedCrossRefGoogle Scholar
  41. 41.
    Wood E, Tyndall MW, Spittal P, et al.: Needle exchange and difficulty with needle access during an ongoing HIV epidemic. Int J Drug Policy 2002, 13:95–102.CrossRefGoogle Scholar
  42. 42.
    Wood E, Li K, Palepu A, et al.: Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users. Subst Use Misuse 2005, 40:1153–1167.PubMedCrossRefGoogle Scholar
  43. 43.
    Wood E, Spittal PM, Li K, et al.: Inability to access addiction treatment and risk of HIV-infection among injection drug users. J Acquir Immune Defic Syndr 2004, 36:750–754.PubMedCrossRefGoogle Scholar
  44. 44.
    Kimber J, Dolan K, van Beek I, et al.: Drug consumption facilities: an update since 2000. Drug Alcohol Rev 2003, 22:227–233.PubMedCrossRefGoogle Scholar
  45. 45.
    Dolan K, Kimber J, Fry C, et al.: Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug Alcohol Rev 2000, 19:337–346.CrossRefGoogle Scholar
  46. 46.
    Wood E, Tyndall MW, Zhang R, et al.: Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med 2006, 354:2512–2514.PubMedCrossRefGoogle Scholar
  47. 47.
    Wood E, Tyndall MW, Zhang R, et al.: Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction 2007, 102:916–919.PubMedCrossRefGoogle Scholar
  48. 48.
    Poschadel S, Höger R, Schnitzler J, Schreckenberg D: Evaluation der Arbeit der Drogenkonsumräume in der Bundesrepublik Deutschland: Endbericht im Auftrag des Bundesministeriums für Gesundheit. Baden-Baden: Nomos-Verlags-Gesellschaft; 2003.Google Scholar
  49. 49.
    Geense R: Evaluation of the Federal measures to reduce the problems related to drug use. To have or to have not: That’s the question: a qualitative study on four low threshold needle exchange serviced for drug users in Switzerland. Lausanne: University Institute of Social and Preventative Medicine; 1997.Google Scholar
  50. 50.
    Palepu A, Tyndall MW, Leon H, et al.: Hospital utilization and costs in a cohort of injection drug users. CMAJ 2001, 165:415–420.PubMedGoogle Scholar
  51. 51.
    Rhodes T, Kimber J, Small W, et al.: Public injecting and the need for ’safer environment interventions’ in the reduction of drug-related harm. Addiction 2006, 101:1384–1393.PubMedCrossRefGoogle Scholar
  52. 52.
    Spreyerman C, Willen C: Evaluationsbericht Öffnung der Kontakt-und Anlaufstellen für risikoärmere Konsumformen. Evaluation der Inhalationsräume der Kontakt und Anlaufstellen Selnau und Seilergraben der Ambulanten Drogenhilfe Zürich. Berne: Sfinx; 2003.Google Scholar
  53. 53.
    Prinzleve M, Martens MS: Evaluation der Abendöffnungszeiten des Drob Inn. Forschungsbericht im Auftrag des Jugendhilfe e.V. Hamburg. Hamburg: Zentrum für Interdisziplinäre Suchtforschung (ZIS); 2003.Google Scholar
  54. 54.
    Thein HH, Kimber J, Maher L, et al.: Public opinion towards supervised injecting centres and the community impact of Sydney Medically Supervised Injecting Centre. Int J Drug Policy 2005, 16:275–280.CrossRefGoogle Scholar
  55. 55.
    Salmon A, Thein R, Kimber J, et al.: Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? Int J Drug Policy 2007, 18:46–53.PubMedCrossRefGoogle Scholar
  56. 56.
    Linssen L, de Jong W, Wolf J: Gebruiksruimten. Een systematisch overzicht van de voorziening en de effecten ervan. Utrecht: Trimbos Instituut; 2001.Google Scholar
  57. 57.
    Stoltz JA, Wood E, Small W, et al.: Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf) 2007, 29:35–39.CrossRefGoogle Scholar
  58. 58.
    Drug situation Spain 2001. Report to the EMCDDA by the Reitox National Focal Point ‘Delegación del Gobierno para el Plan Nacional Sobre Drogas’. Madrid: Plan Nactional Sobre Drogras (PND); 2002.Google Scholar
  59. 59.
    Small W, Wood E, Tyndall M, et al.: Accessing care for injection-related infections through a medically supervised safer injection facility: the perspectives of injection drug users. Can J Infect Dis 2007, 18(Suppl B):18B.Google Scholar
  60. 60.
    Tyndall MW, Craib KJ, Currie S, et al.: Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001, 28:351–357.PubMedGoogle Scholar
  61. 61.
    Bluthenthal RN, Kral AH, Lorvick J, et al.: Harm reduction and needle exchange programmes [letter; comment]. Lancet 1998, 351:1333.CrossRefGoogle Scholar
  62. 62.
    National Institutes of Health/National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction: Effective medical treatment of opiate addiction. JAMA 1988, 280:1936–1943.CrossRefGoogle Scholar
  63. 63.
    Böllinger L, Stöver H, Fietzek L, eds: Druckräume: Angebote, in denen der intravenöse Drogenkonsum toleriert wird. In Drogenpraxis, Drogenrecht, Drogenpolitik. Frankfurt: Fachhochschulverlag; 1995:142–145.Google Scholar
  64. 64.
    Beek I, Kimber J, Dakin A, Gilmour S: The Sydney Medically Supervised Injecting Centre: reducing harm associated with heroin overdose. Critical Public Health 2004, 14:391–406.CrossRefGoogle Scholar
  65. 65.
    Kerr T, Tyndall M, Lai C, et al.: Drug-related overdoses within a medically supervised safer injection facility. Int J Drug Policy 2006, 17:436–441.CrossRefGoogle Scholar
  66. 66.
    Wurcel A, Zaman T, Zhen S, Stone D: Acceptance of HIV antibody testing among inpatients and outpatients at a public health hospital: a study of rapid versus standard testing. AIDS Patient Care STDS 2005, 19:499–505.PubMedCrossRefGoogle Scholar
  67. 67.
    Wood E, Kerr T, Hogg RS, et al.: Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Drug Alcohol Rev 2006, 25:451–454.PubMedCrossRefGoogle Scholar
  68. 68.
    Wood E, Hogg RS, Bonner S, et al.: Staging for antiretroviral therapy among HIV-infected drug users. JAMA 2004, 292:1175–1177.PubMedCrossRefGoogle Scholar
  69. 69.
    Wood E, Lloyd-Smith E, Li K, et al.: Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am J Med 2007, 120:172–179.PubMedCrossRefGoogle Scholar
  70. 70.
    Kerr T, Craib KJ, Gataric N, Hogg RS: Assessing the impact of an adult day program on hospital utilization by persons living with HIV/AIDS. J Acquir Immune Defic Syndr 2002, 31:117–119.PubMedGoogle Scholar
  71. 71.
    Petrar S, Kerr T, Tyndall MW, et al.: Injection drug users’ perceptions regarding use of a medically supervised safer injecting facility. Addict Behav 2007, 32:1088–1093.PubMedCrossRefGoogle Scholar
  72. 72.
    Kerr T, Small D, Moore D, Wood E: A micro-environmental intervention to reduce the harms associated with drug-related overdose: Evidence from the evaluation of Vancouver’s safer injection facility. Int J Drug Policy 2007, 18:37–45.PubMedCrossRefGoogle Scholar
  73. 73.
    Kimber J, Hickman M, Degenhardt L, et al.: Estimating the size of the local IDU population using client visits to the Sydney Medically Supervised Injecting Centre. Paper presented at the 16th International Conference on the Reduction of Drug Related Harm. Belfast, Ireland; March 20–24, 2005.Google Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.BC Centre for Excellence in HIV/AIDSUniversity of British Columbia, St. Paul’s HospitalVancouverCanada

Personalised recommendations